Recent Updates — EPRX

Eupraxia Pharmaceuticals announced that its management team will participate in several upcoming industry events, including the Craig Hallum Biotech Catalyst Virtual Conference, BIO-Europe, Stifel 2026 Healthcare Conference, and the Jefferies Global Healthcare Conference. The company will also host a virtual Analyst Day on November 13, 2026, to discuss its investigational product EP-104GI for Eosinophilic Esophagitis (EoE). These engagements are scheduled between October and November 2026. Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products using its proprietary Diffusphere technology to address therapeutic areas with high unmet medical need.

Eupraxia Pharmaceuticals has reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis. The company confirmed that statistical reviews indicate no adjustment to the sample size is required. Over 3,000 injections have been administered across Phase 1b/2a and Phase 2b with no treatment-related serious adverse events. Interim analysis of the Phase 2b portion is expected in December 2026. Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biotechnology company focused on developing locally delivered, extended-release products using its proprietary Diffusphere technology.

Eupraxia Pharmaceuticals will present three abstracts regarding its ongoing Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE) at the American College of Gastroenterology (ACG) meeting in Nashville and United European Gastroenterology (UEG) Week in Barcelona. The presentations highlight improvements in dysphagia, histopathological features, and symptom severity following single administrations of escalating doses during dose escalation cohorts. Interim data from the Phase 2b portion of the trial are expected in December 2026. Eupraxia is a clinical-stage biotechnology company focused on developing locally delivered, extended-release products using its proprietary Diffusphere technology.

Eupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in patients with eosinophilic esophagitis (EoE). In Cohorts 7-9, the proportion of patients experiencing moderate to severe odynophagia decreased from 62% at baseline to 25% at weeks 24 and 52 post-treatment. Severe odynophagia was reported by 15% of patients at baseline but by no patients at week 52. Similarly, moderate to severe dysphagia dropped from 77% at baseline to 25% at weeks 24 and 52, with severe cases eliminating entirely post-treatment. The drug demonstrated a favorable safety profile with over 130 patients treated across more than 2,000 injection sites and no serious adverse events reported. Eupraxia anticipates interim data from the Phase 2b placebo-controlled portion of the trial in Q4 2026. This company operates as a clinical-stage biotechnology firm developing locally delivered, extended-release products using its proprietary Diffusphere technology for therapeutic areas with high unmet medical need.